TGNA:FRA
Transgene SA
0,67 €
arrow_downward
-0,59%(-0,0040) 1D
14 ოქტ, 08:03:02 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TGNA...
Open
0,67 €
High
0,67 €
Low
0,67 €
Mkt. cap
191,38 მლნ.
Avg. vol.
0,00
Volume
0,00
52-wk high
1,48 €
52-wk low
0,60 €
EPS
-0,17 €
No. of employees
152
Open
0,67 €
High
0,67 €
Low
0,67 €
Mkt. cap
191,38 მლნ.
Avg. vol.
0,00
Volume
0,00
52-wk high
1,48 €
52-wk low
0,60 €
EPS
-0,17 €
No. of employees
152
News stories
From web sources and news partners
GlobeNewswire
·
10 წუთის წინ
Owlting Group (NASDAQ: OWLS) and Decaf Open U.S. Dollar Accounts Beyond the United States on OwlPay Harbor
StockStory
·
38 წუთის წინ
1 S&P 500 Stock with Competitive Advantages and 2 We Brush Off
Investor's Business Daily
·
39 წუთის წინ
Dow Futures Rise; ASML Earnings Beat, CPI Inflation Due
Seeking Alpha
·
2 საათის წინ
Dow Jones Industrial Average Monitor Update - A Look At 30 U.S. Large-Caps
Profile
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
About Transgene SA